MIT Technology Review Subscribe

The US says not to give Johnson & Johnson vaccines after a woman died from a rare blood clot

Evidence is mounting that one type of covid-19 vaccine causes rare and deadly side effects.

covid janssen vaccine vials

The US took the dramatic step of recommending that health-care providers stop giving people the Johnson & Johnson vaccine against covid-19 after six women who received it developed serious blood clots and one died.

The US Food and Drug Administration described its action as a temporary halt to give regulators time to understand the apparent side effect. “We are recommending a pause in the use of this vaccine out of an abundance of caution,” the agency said in a statement.

Advertisement

As of Monday, April 12, about 6.8 million doses of the J&J vaccine had been given in the US. That means the rate of the serious clotting events could be about 1 in 1 million, making them “extremely rare,” according to the FDA. 

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in

By comparison, about 1 in 600 Americans have already died of covid-19 or with the infection as a contributing factor, meaning getting infected by the coronavirus is the much greater risk overall.

The problem is that the blood clots have struck younger women, whose personal risk from covid-19 is lower.  

The women, all between the ages of 18 and 48, developed serious blood clots six to 13 days after getting the vaccine, the FDA said in a statement. According to the New York Times, one died and another is in critical condition.

That means people who have gotten the J&J vaccine recently should be on the lookout for a severe headache, pain in the abdomen or legs, and shortness of breath. After about two weeks the risk seems to pass.

The government warned that the type of clot being seen—called a cerebral venous sinus thrombosis—is very unusual and that heparin, a common blood thinner often used to treat clots, could be dangerous in these cases. A group of advisors to the US Centers for Disease Control will meet Wednesday, April 14, to review the cases and “assess their potential significance.”

In statement, Johnson & Johnson said it was “aware of an extremely rare disorder” involving vaccine recipients and said it had decided to postpone the rollout of its vaccine in Europe.

Blood clots have also been linked to another vaccine, from AstraZeneca, which has been widely used in Europe but is not yet authorized in the US. Regulators in Europe have in some cases recommended that younger people avoid that vaccine.

Advertisement

Both the J&J and AstraZeneca vaccines employ an adenovirus, a supposedly harmless component. Now scientists will investigate whether the adenovirus, or another aspect of the vaccine, causes an immune reaction that is leading to the clots.

The two most widely used vaccines in the US, sold by Moderna and Pfizer, are mRNA vaccines that employ a different technology. Those vaccines often cause muscle aches and fever but haven’t been linked to blood clots.

The pause announced by the FDA is likely to curtail the use of the J&J shot at federal vaccine sites. States and hospitals can choose to keep giving it depending on the age and risk profile of the patient, although several governors, as well as the CVS and Walgreens pharmacy chains, said they would also pause the shots, the New York Times reported. 

The J&J vaccine requires a single shot and is more convenient than the Moderna and Pfizer vaccines, which both require two doses. However, the company’s manufacturing was plagued by problems. Now, with concern over side effects, the role it plays in the US response may become even more limited.

1 free story remaining
This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement